Clinical cancer research : an official journal of the American Association for Cancer Research
Huang PS.
PMID: 22392916
Clin Cancer Res. 2012 Apr 15;18(8):2124-6. doi: 10.1158/1078-0432.CCR-12-0461. Epub 2012 Mar 05.
The rationale for using multiple inhibitors between and within the phosphoinositide 3-kinase/AKT/mTOR and RAS/MEK/ERK pathways is scientifically compelling, and a limited number of experimental agents are currently being tested in phase I combinations. Patient subpopulations, whose tumors are defined...
Cite
Huang PS. Double down for a double win. Clin Cancer Res. 2012;18(8):2124-6doi: 10.1158/1078-0432.CCR-12-0461.
Huang, P. S. (2012). Double down for a double win. Clinical cancer research : an official journal of the American Association for Cancer Research, 18(8), 2124-6. https://doi.org/10.1158/1078-0432.CCR-12-0461
Huang, Pearl S. "Double down for a double win." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 18,8 (2012): 2124-6. doi: https://doi.org/10.1158/1078-0432.CCR-12-0461
Huang PS. Double down for a double win. Clin Cancer Res. 2012 Apr 15;18(8):2124-6. doi: 10.1158/1078-0432.CCR-12-0461. Epub 2012 Mar 05. PMID: 22392916.
Copy
Download .nbib
Molecular cancer research : MCR
Barbosa R, Acevedo LA, Marmorstein R.
PMID: 33139506
Mol Cancer Res. 2021 Mar;19(3):361-374. doi: 10.1158/1541-7786.MCR-20-0687. Epub 2020 Nov 02.
The RAS-RAF-MEK-ERK pathway is the most well-studied of the MAPK cascades and is critical for cell proliferation, differentiation, and survival. Abnormalities in regulation resulting from mutations in components of this pathway, particularly in upstream proteins, RAS and RAF, are...
Cite
Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK Network as a Therapeutic Target in Human Cancer. Mol Cancer Res. 2020;19(3):361-374doi: 10.1158/1541-7786.MCR-20-0687.
Barbosa, R., Acevedo, L. A., & Marmorstein, R. (2021). The MEK/ERK Network as a Therapeutic Target in Human Cancer. Molecular cancer research : MCR, 19(3), 361-374. https://doi.org/10.1158/1541-7786.MCR-20-0687
Barbosa, Renee, et al. "The MEK/ERK Network as a Therapeutic Target in Human Cancer." Molecular cancer research : MCR vol. 19,3 (2021): 361-374. doi: https://doi.org/10.1158/1541-7786.MCR-20-0687
Barbosa R, Acevedo LA, Marmorstein R. The MEK/ERK Network as a Therapeutic Target in Human Cancer. Mol Cancer Res. 2021 Mar;19(3):361-374. doi: 10.1158/1541-7786.MCR-20-0687. Epub 2020 Nov 02. PMID: 33139506; PMCID: PMC7925338.
Copy
Download .nbib
Cancer cell
Hey F, Pritchard C.
PMID: 23680140
Cancer Cell. 2013 May 13;23(5):561-3. doi: 10.1016/j.ccr.2013.04.021.
ERK pathway activation in cells expressing wild-type BRAF is a well-reported, clinically-relevant adverse effect of the otherwise impressive response of BRAF(V600E)-mutated melanomas to RAF inhibitors. In this issue of Cancer Cell, Holderfield and colleagues show that RAF autoinhibition underpins...
Cite
Hey F, Pritchard C. A new mode of RAF autoregulation: a further complication in the inhibitor paradox. Cancer Cell. 2013;23(5):561-3doi: 10.1016/j.ccr.2013.04.021.
Hey, F., & Pritchard, C. (2013). A new mode of RAF autoregulation: a further complication in the inhibitor paradox. Cancer cell, 23(5), 561-3. https://doi.org/10.1016/j.ccr.2013.04.021
Hey, Fiona, and Pritchard, Catrin. "A new mode of RAF autoregulation: a further complication in the inhibitor paradox." Cancer cell vol. 23,5 (2013): 561-3. doi: https://doi.org/10.1016/j.ccr.2013.04.021
Hey F, Pritchard C. A new mode of RAF autoregulation: a further complication in the inhibitor paradox. Cancer Cell. 2013 May 13;23(5):561-3. doi: 10.1016/j.ccr.2013.04.021. PMID: 23680140.
Copy
Download .nbib
